Compare WYETH with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH vs ASTRAZENECA PHARMA - Comparison Results

WYETH     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH ASTRAZENECA PHARMA WYETH/
ASTRAZENECA PHARMA
 
P/E (TTM) x 27.7 115.2 24.1% View Chart
P/BV x 5.3 35.3 15.2% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 WYETH   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    WYETH
Mar-13
ASTRAZENECA PHARMA
Mar-18
WYETH/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0441,278 81.7%   
Low Rs818883 92.7%   
Sales per share (Unadj.) Rs298.6228.4 130.7%  
Earnings per share (Unadj.) Rs57.210.4 552.3%  
Cash flow per share (Unadj.) Rs58.416.3 359.2%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.80-  
Book value per share (Unadj.) Rs249.598.8 252.6%  
Shares outstanding (eoy) m22.7225.00 90.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.14.7 65.9%   
Avg P/E ratio x16.3104.2 15.6%  
P/CF ratio (eoy) x15.966.4 24.0%  
Price / Book Value ratio x3.710.9 34.1%  
Dividend payout %29.70-   
Avg Mkt Cap Rs m21,15727,008 78.3%   
No. of employees `0000.51.4 36.3%   
Total wages/salary Rs m4001,535 26.1%   
Avg. sales/employee Rs Th13,787.44,210.9 327.4%   
Avg. wages/employee Rs Th813.01,132.2 71.8%   
Avg. net profit/employee Rs Th2,643.3191.1 1,383.4%   
INCOME DATA
Net Sales Rs m6,7835,710 118.8%  
Other income Rs m353123 287.8%   
Total revenues Rs m7,1365,833 122.3%   
Gross profit Rs m1,617463 349.4%  
Depreciation Rs m27147 18.0%   
Interest Rs m60-   
Profit before tax Rs m1,938438 442.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m632179 353.4%   
Profit after tax Rs m1,301259 501.9%  
Gross profit margin %23.88.1 294.1%  
Effective tax rate %32.640.8 79.9%   
Net profit margin %19.24.5 422.5%  
BALANCE SHEET DATA
Current assets Rs m6,9843,209 217.6%   
Current liabilities Rs m2,0562,070 99.3%   
Net working cap to sales %72.620.0 364.0%  
Current ratio x3.41.6 219.1%  
Inventory Days Days9972 137.2%  
Debtors Days Days2435 68.6%  
Net fixed assets Rs m244790 30.9%   
Share capital Rs m22750 454.4%   
"Free" reserves Rs m5,4412,419 224.9%   
Net worth Rs m5,6682,469 229.5%   
Long term debt Rs m250-   
Total assets Rs m7,9014,605 171.6%  
Interest coverage x353.3NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.2 69.2%   
Return on assets %16.55.6 293.8%  
Return on equity %22.910.5 218.7%  
Return on capital %34.017.7 191.9%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m15300 5.1%   
Fx outflow Rs m2,6772,015 132.9%   
Net fx Rs m-2,662-1,715 155.2%   
CASH FLOW
From Operations Rs m92388 1,050.3%  
From Investments Rs m317-94 -338.6%  
From Financial Activity Rs m-481NA-  
Net Cashflow Rs m759-6 -13,317.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.1 75.0 68.1%  
Indian inst/Mut Fund % 11.3 0.3 3,766.7%  
FIIs % 7.2 15.7 45.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 9.1 334.1%  
Shareholders   21,978 12,856 171.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH With:   SUVEN LIFE SCIENCES  NEULAND LABS  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare WYETH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Surged 1,147 Points Today(Closing)

Indian share markets continued their momentum and ended their day on a strong note today.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

WYETH SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH

COMPARE WYETH WITH

MARKET STATS